Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $9.4 million.

  • 4D Molecular Therapeutics' Other Non-Current Assets rose 227.51% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year increase of 227.51%. This contributed to the annual value of $4.3 million for FY2024, which is 522.95% up from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Other Non-Current Assets stood at $9.4 million, which was down 0.11% from $9.4 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Other Non-Current Assets' 5-year high stood at $9.4 million during Q2 2025, with a 5-year trough of $602,000 in Q1 2021.
  • Its 3-year average for Other Non-Current Assets is $3.6 million, with a median of $2.3 million in 2024.
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Other Non-Current Assets tumbled by 38.81% in 2024, and later soared by 813.49% in 2025.
  • Quarterly analysis of 5 years shows 4D Molecular Therapeutics' Other Non-Current Assets stood at $602,000 in 2021, then surged by 79.40% to $1.1 million in 2022, then tumbled by 36.67% to $684,000 in 2023, then spiked by 522.95% to $4.3 million in 2024, then soared by 227.51% to $9.4 million in 2025.
  • Its Other Non-Current Assets was $9.4 million in Q3 2025, compared to $9.4 million in Q2 2025 and $7.0 million in Q1 2025.